Skip to main content Accessibility help
×
Home

Cognitive impairment in major depressive disorder

  • Zihang Pan (a1) (a2), Caroline Park (a1) (a2), Elisa Brietzke (a1) (a3), Hannah Zuckerman (a1), Carola Rong (a1), Rodrigo B. Mansur (a1) (a4), Dominika Fus (a1), Mehala Subramaniapillai (a1), Yena Lee (a1) (a2) and Roger S. McIntyre (a1) (a2) (a4) (a5)...

Abstract

Cognitive dysfunction is a symptomatic domain identified across many mental disorders. Cognitive deficits in individuals with major depressive disorder (MDD) contribute significantly to occupational and functional disability. Notably, cognitive subdomains such as learning and memory, executive functioning, processing speed, and attention and concentration are significantly impaired during, and between, episodes in individuals with MDD. Most antidepressants have not been developed and/or evaluated for their ability to directly and independently ameliorate cognitive deficits. Multiple interacting neurobiological mechanisms (eg, neuroinflammation) are implicated as subserving cognitive deficits in MDD. A testable hypothesis, with preliminary support, posits that improving performance across cognitive domains in individuals with MDD may improve psychosocial function, workplace function, quality of life, and other patient-reported outcomes, independent of effects on core mood symptoms. Herein we aim to (1) provide a rationale for prioritizing cognitive deficits as a therapeutic target, (2) briefly discuss the neurobiological substrates subserving cognitive dysfunction, and (3) provide an update on current and future treatment avenues.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cognitive impairment in major depressive disorder
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cognitive impairment in major depressive disorder
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cognitive impairment in major depressive disorder
      Available formats
      ×

Copyright

Corresponding author

*Address for correspondence: Roger S. McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto, Head, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. (Email: roger.mcintyre@uhn.ca)

References

Hide All
1. Fagiolini, A, Forgione, R, Maccari, M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013; 148(2–3): 161169.
2. Marcus, M, Yasamy, MT, Ommeren, MV, Chisholm, D, Saxena, S. Depression: a global public health concern. 2012. http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf. Accessed July 22, 2014.
3. Collins, PY, Patel, V, Joestl, SS, et al. Grand challenges in global mental health. Nature. 2011; 475(7354): 2730.
4. Cha, DS, Carmona, NE, Subramaniapillai, M, et al. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): association with psychosocial function in major depressive disorder. J Affect Disord. 2017; 222: 1420.
5. Woo, YS, Rosenblat, JD, Kakar, R, Bahk, W-M, McIntyre, RS. Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients. Clin Psychopharmacol Neurosci. 2016; 14(1): 116.
6. McIntyre, RS, Cha, DS, Soczynska, JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013; 30(6): 515527.
7. McIntyre, RS, Lee, Y. Cognition in major depressive disorder: a “Systemically Important Functional Index” (SIFI). Curr Opin Psychiatry. 2016; 29(1): 4855.
8. Rosenblat, JD, Kakar, R, McIntyre, RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015; 19(2): pyv082. doi: 10.1093/ijnp/pyv082
9. Pan, Z, Grovu, RC, Cha, DS, et al. Pharmacological treatment of cognitive symptoms in major depressive disorder. CNS Neurol Disord Drug Targets. 2017; 16(8): 891899. doi:10.2174/1871527316666170919115100
10. Rosenblat, JD, Brietzke, E, Mansur, RB, Maruschak, NA, Lee, Y, McIntyre, RS. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: evidence, pathophysiology and treatment implications. J Affect Disord. 2015; 188: 149159.
11. Carvalho, AF, Berk, M, Hyphantis, TN, McIntyre, RS. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 2014; 83(2): 7088.
12. McIntyre, RS, Cha, DS, Soczynska, JK. Cognition in Major Depressive Disorder. Oxford, UK: Oxford University Press; 2014.
13. Jantaratnotai, N, Mosikanon, K, Lee, Y, McIntyre, RS. The interface of depression and obesity. Obes Res Clin Pract. 2017; 11(1): 110.
14. Mansur, RB, Lee, Y, Zhou, AJ, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: a meta-analysis. Ann Clin Psychiatry. 2018; 30(1): 3850.
15. Harrison, JE, Lam, RW, Baune, BT, McIntyre, RS. Selection of cognitive tests for trials of therapeutic agents. Lancet Psychiatry. 2016; 3(6): 499.
16. McIntyre, RS, Woldeyohannes, HO, Soczynska, JK, et al. Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. CNS Spectr. 2016; 21(5): 362366.
17. McIntyre, RS, Xiao, HX, Syeda, K, et al. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 2015; 29(7): 577589.
18. Roiser, JP, Sahakian, BJ. Hot and cold cognition in depression. CNS Spectr. 2013; 18(3): 139149.
19. Stahl, SM. Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 2010; 15(2): 7994.
20. Bortolato, B, Carvalho, AF, Soczynska, JK, Perini, GI, McIntyre, RS. The involvement of TNF-α in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments. Curr Neuropharmacol 2015; 13(5): 558576.
21. Rosenblat, JD, Cha, DS, Mansur, RB, McIntyre, RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 53: 2334.
22. Shariq, AS, Brietzke, E, Rosenblat, JD, Barendra, V, Pan, Z, McIntyre, RS. Targeting cytokines in reduction of depressive symptoms: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 83: 8691.
23. Jiao, Q, Ding, J, Lu, G, et al. Increased activity imbalance in fronto-subcortical circuits in adolescents with major depression. PLoS One 2011; 6(9): e25159.
24. Pizzagalli, DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology. 2011; 36(1): 183206.
25. MacQueen, GM, Campbell, S, McEwen, BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A. 2003; 100(3): 13871392.
26. Stahl, SM, Zhang, L, Damatarca, C, Grady, M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003; 64(Suppl 14): 617.
27. Kheirbek, MA, Hen, R. Dorsal vs ventral hippocampal neurogenesis: implications for cognition and mood. Neuropsychopharmacology 2011; 36(1): 373374.
28. Malykhin, NV, Carter, R, Seres, P, Coupland, NJ. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci. 2010; 35(5): 337343.
29. Gorwood, P, Corruble, E, Falissard, B, Goodwin, GM. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry. 2008; 165(6): 731739.
30. Zeng, L-L, Shen, H, Liu, L, et al. Identifying major depression using whole-brain functional connectivity: a multivariate pattern analysis. Brain 2012; 135(Pt 5): 14981507.
31. Harvey, P-O, Fossati, P, Pochon, J-B, et al. Cognitive control and brain resources in major depression: an fMRI study using the n-back task. Neuroimage 2005; 26(3): 860869.
32. Hamilton, JP, Furman, DJ, Chang, C, Thomason, ME, Dennis, E, Gotlib, IH. Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. Biol Psychiatry 2011; 70(4): 327333.
33. Cha, DS, De Michele, F, Soczynska, JK, et al. The putative impact of metabolic health on default mode network activity and functional connectivity in neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2014; 13(10): 17501758.
34. Li, M, Soczynska, JK, Kennedy, SH. Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr Psychiatry Rep. 2011; 13(5): 316320.
35. Ryan, JP, Sheu, LK, Critchley, HD, Gianaros, PJ. A neural circuitry linking insulin resistance to depressed mood. Psychosom Med 2012; 74(5): 476482.
36. Andreazza, AC. Combining redox-proteomics and epigenomics to explain the involvement of oxidative stress in psychiatric disorders. Mol Biosyst 2012; 8(10): 25032512.
37. McAfoose, J, Baune, BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009; 33(3): 355366.
38. McIntyre, RS, Rasgon, NL, Kemp, DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep. 2009; 9(1): 5159.
39. Baker, LD, Cross, DJ, Minoshima, S, Belongia, D, Watson, GS, Craft, S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011; 68(1): 5157.
40. Hidese, S, Ota, M, Matsuo, J, et al. Association of obesity with cognitive function and brain structure in patients with major depressive disorder. J Affect Disord. 2018; 225: 188194.
41. Buist-Bouwman, MA, Ormel, J, de Graaf, R, et al. Mediators of the association between depression and role functioning. Acta Psychiatr Scand. 2008; 118(6): 451458.
42. McIntyre, RS, Soczynska, JZ, Woldeyohannes, HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry 2015; 56: 279282.
43. McIntyre, RS, Cha, DS. Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates, and Treatment Opportunities. Cambridge, UK: Cambridge University Press; 2016.
44. Medalia, A, Revheim, N, Herlands, T. Cognitive Remediation for Psychological Disorders. Oxford, UK: Oxford University Press; 2009.
45. Bowie, CR, Gupta, M, Holshausen, K, Jokic, R, Best, M, Milev, R. Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J Nerv Ment Dis. 2013; 201(8): 680685.
46. Bowie, CR, McGurk, SR, Mausbach, B, Patterson, TL, Harvey, PD. Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. Am J Psychiatry. 2012; 169(7): 710718.
47. Porter, RJ, Bowie, CR, Jordan, J, Malhi, GS. Cognitive remediation as a treatment for major depression: a rationale, review of evidence and recommendations for future research. Aust N Z J Psychiatry. 2013; 47(12): 11651175.
48. Siegle, GJ, Thompson, W, Carter, CS, Steinhauer, SR, Thase, ME. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry 2007; 61(2): 198209.
49. Ragguett R-M, Cha DS, Kakar R, Rosenblat JD, Lee Y, McIntyre RS. Assessing and measuring cognitive function in major depressive disorder. Evid Based Ment Health. 2016; 19(4): 106–109.
50. Mohlman, J, Deckersbach, T, Weissman, A. From Symptom to Synapse: A Neurocognitive Perspective on Clinical Psychology. New York: Routledge; 2015.
51. Lazar, MA, Pan, Z, Ragguett, R-M, et al. Digital revolution in depression: a technologies update for clinicians. Personalized Medicine in Psychiatry. 2017; 4–6: 16.
52. Lam, RW, Parikh, SV, Ramasubbu, R, et al. Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. Br J Psychiatry. 2013; 203(5): 358365.
53. Parikh, SV, Quilty, LC, Ravitz, P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. psychological treatments. Can J Psychiatry. 2016; 61(9): 524539.
54. Young, S, Khondoker, M, Emilsson, B, et al. Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis. Psychol Med 2015; 45(13): 27932804.
55. Serafini, G, Pompili, M, Belvederi Murri, M, et al. The effects of repetitive transcranial magnetic stimulation on cognitive performance in treatment-resistant depression: a systematic review. Neuropsychobiology 2015; 71(3): 125139.
56. Demirtas-Tatlidede, A, Vahabzadeh-Hagh, AM, Pascual-Leone, A. Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Neuropharmacology 2013; 64: 566578.
57. Kuroda Y, Motohashi N, Ito H, Ito S, Takano A, Nishikawa T, et al. Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression. J Affect Disord. 2006; 95(1-3): 35–42.
58. Smith, PJ, Blumenthal, JA, Hoffman, BM, et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med 2010; 72(3): 239252.
59. Stanton, R, Reaburn, P. Exercise and the treatment of depression: a review of the exercise program variables. J Sci Med Sport. 2014; 17(2): 177182.
60. Hillman, CH, Kamijo, K, Scudder, M. A review of chronic and acute physical activity participation on neuroelectric measures of brain health and cognition during childhood. Prev Med 2011; 52(Suppl 1): S21S28.
61. Heyn, P, Abreu, BC, Ottenbacher, KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil. 2004; 85(10): 16941704.
62. Soczynska, JK, Ravindran, LN, Styra, R, et al. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res 2014; 220(1–2): 245250.
63. Constant, EL, Adam, S, Gillain, B, Seron, X, Bruyer, R, Seghers, A. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety 2005; 21(2): 7889.
64. Schrijvers, D, Maas, YJ, Pier, MP, Madani, Y, Hulstijn, W, Sabbe, BG. Psychomotor changes in major depressive disorder during sertraline treatment. Neuropsychobiology 2009; 59(1): 3442.
65. Raskin, J, Wiltse, CG, Siegal, A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007; 164(6): 900909.
66. McIntyre, RS, Lophaven, S, Olsen, CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014; 17(10): 15571567.
67. McIntyre, RS, Harrison, J, Loft, H, Jacobson, W, Olsen, CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016; 19(10): pyw055. doi: 10.1093/ijnp/pyw055
68. Mahableshwarkar, AR, Zajecka, J, Jacobson, W, Chen, Y, Keefe, RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2015; 40(8): 20252037.
69. Madhoo, M, Keefe, RSE, Roth, RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology 2014; 39(6): 13881398.
70. Venero, C. Pharmacological treatment of cognitive dysfunction in neuropsychiatric disorders. In: Knafo S, Venero C, eds. Cognitive Enhancement: Pharmacologic, Environmental and Genetic Factors. San Diego, CA: Academic Press; 2015: 233271.
71. Lee, Y, Syeda, K, Maruschak, NA, et al. A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect. J Clin Psychopharmacol. 2016; 36(1): 5056.
72. Mansur, RB, Ahmed, J, Cha, DS, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord. 2017; 207: 114120.
73. Raison, CL, Rutherford, RE, Woolwine, BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013; 70(1): 3141.
74. Raison, CL, Miller, AH Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun. 2013; 31: 18.
75. Loftus, EV, Feagan, BG, Colombel, J-F, et al. Corrigendum: effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM Trial. Am J Gastroenterol. 2009; 104: 1894.
76. Persoons, P, Vermeire, S, Demyttenaere, K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005; 22(2): 101110.
77. Tookman, AJ, Jones, CL, DeWitte, M, Lodge, PJ. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer. 2008; 16(10): 11311140.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed